President and CEO,
Pharmaceutical Research and Manufacturers of America (PhRMA)
As head of PhRMA since 2015, Ubl has worked to promote a legislative environment that encourages medical innovation, drug discoveries and access to life-saving medicines. According to the association, the U.S. biopharmaceutical industry invests more than $100 billion in research and development each year. Ubl has called on President Joe Biden to keep international waivers approved during the pandemic from eroding intellectual property rights of U.S. drugmakers, warning of the potential to undermine the global efforts that produce vaccines and other treatment breakthroughs. The association opposed Medicare’s authority to negotiate drug prices, which is provided under the Inflation Reduction Act. Ubl was previously president and CEO of medical technology association AdvaMed.